US Patent 7,459,428: Scope, Claim Construction, Expiration Risk and DPP-4 Inhibitor Patent Landscape

US Patent 7,459,428 protects a method of treating Type II diabetes by conjointly administering metformin with a dipeptidyl peptidase IV inhibitor at a dose that treats diabetes without producing immunosuppression. The independent claim is a combination-treatment claim, not a claim to metformin, a particular DPP-4 inhibitor, a formulation, or a chemical compound.

The principal commercial significance is the breadth of claim 1. It can potentially reach combinations of metformin with multiple structurally unrelated DPP-4 inhibitors, provided the accused use satisfies the therapeutic, dosing, and non-immunosuppressive limitations. Claims 9 through 20 narrow the estate to defined inhibitor classes and chemical formulae. Claims 21 through 24 address administration logistics and same-composition products.

The patent issued on December 9, 2008. Its current enforceability depends on the patent’s effective filing date, any patent-term adjustment, terminal disclaimer, maintenance-fee history, reexamination or post-grant proceedings, and claim amendments. Those issues cannot be established from the claim text alone.

What does US Patent 7,459,428 protect?

The patent protects a method of treating Type II diabetes using two pharmacological components:

Metformin.
A DPP-4 inhibitor or pharmaceutically acceptable salt.

The two agents must be administered “conjointly.” The claims expressly include simultaneous, sequential, separate, and same-composition dosing.

The required DPP-4 inhibitor dose must be sufficient to participate in treatment of Type II diabetes but insufficient to suppress the animal’s immune system. This limitation distinguishes the claimed use from DPP-4 inhibitor dosing directed to immunomodulation.

Claim architecture

Claim group	Subject matter	Practical scope
Claim 1	Metformin plus DPP-4 inhibitor for Type II diabetes	Broadest method claim
Claims 2-3	Metabolic effects and selectivity against immunosuppression	Functional narrowing
Claims 4-5	DPP-4 Ki of 10 nM or less, or 1 nM or less	Potency limitations
Claim 6	Inhibitor molecular weight below 7,500 amu	Broad size limitation
Claim 7	Oral administration	Covers oral treatment
Claim 8	Peptidomimetics based on Pro-Pro, Ala-Pro or D-Ala-L-Ala	Structural narrowing
Claims 9-20	Formula-defined inhibitor classes	Chemical genus and subgenus claims
Claims 21-24	Simultaneous, sequential, separate or same-composition dosing	Administration-mode coverage

How broad is independent claim 1?

Claim 1 is broad in the identity of the DPP-4 inhibitor. It does not name sitagliptin, vildagliptin, saxagliptin, linagliptin, alogliptin or any other marketed DPP-4 inhibitor. Instead, it uses the functional term “an inhibitor of dipeptidylpeptidase IV.”

That breadth is constrained by four elements:

The patient must be an animal, with the intended application being Type II diabetes.
Metformin must be administered.
A DPP-4 inhibitor or pharmaceutically acceptable salt must also be administered.
The inhibitor amount must be insufficient to suppress the immune system.

The claim does not expressly require:

A particular metformin dose.
A fixed metformin-to-DPP-4-inhibitor ratio.
A particular dosing sequence.
A fixed duration of treatment.
A particular route of metformin administration.
A fixed degree of DPP-4 inhibition.
A fixed reduction in HbA1c.
A fixed formulation or dosage form.

The claim therefore targets the therapeutic combination and its use, rather than the product configuration alone.

Claim construction issues

The phrase “conjointly administering” is expanded by claims 21 through 24. The patent’s claim set indicates that conjoint administration includes:

Simultaneous dosing.
Sequential dosing.
Separate dosing.
Dosing in the same composition.

An accused product need not be a fixed-dose combination to fall within the literal scope of claim 1. A treatment regimen using metformin and a separately marketed DPP-4 inhibitor may be relevant if the other limitations are met.

The non-immunosuppression limitation is likely to create the largest factual dispute. A patent owner would need to establish that the administered amount is not sufficient to suppress the immune system. An accused party could challenge the limitation as indefinite, unsupported, not enabled across the full breadth of the claim, or absent from the relevant treatment protocol.

What do claims 2 through 8 add?

Claims 2 through 8 provide narrower fallback positions.

Claim 2 covers treatment in which the DPP-4 inhibitor reduces one or more of insulin resistance, glucose intolerance, hyperglycemia or hyperinsulinemia. The claim does not require reduction of every listed condition. A therapy producing one listed effect may satisfy the limitation if the claim is construed disjunctively.

Claim 3 imposes a pharmacological selectivity requirement. The inhibitor must have an EC50 for modifying glucose metabolism at least one order of magnitude lower than its EC50 for immunosuppression. This is a 10-fold selectivity relationship.

Claims 4 and 5 define potency using Ki values:

Claim	Required DPP-4 Ki
Claim 4	10 nM or less
Claim 5	1.0 nM or less

These claims raise measurement questions. The relevant assay, enzyme source, substrate, temperature, pH, competitive or noncompetitive model, and treatment of salt or prodrug forms can materially affect Ki. A litigation analysis would compare the patent’s disclosed assay methodology with the accused party’s data.

Claim 6 covers inhibitors with molecular weight below 7,500 amu. That threshold is so high relative to conventional small-molecule DPP-4 inhibitors that it is unlikely to be the principal commercial limitation. It could, however, cover certain peptide or peptidomimetic inhibitors.

Claim 7 requires oral administration of the inhibitor. It may reach oral tablets, capsules, orally administered solutions and oral fixed-dose combinations, assuming the other elements are satisfied.

Claim 8 identifies peptidomimetics based on Pro-Pro, Ala-Pro or D-Ala-L-Ala peptide sequences. This claim is narrower and more vulnerable to prosecution-history and written-description issues than claim 1 because the claimed class depends on the patent’s disclosed structural definition of “peptidomimetic.”

What chemical matter is covered by claims 9 through 20?

Claims 9 through 20 cover formula-defined classes of DPP-4 inhibitors. The supplied claim text describes compounds containing combinations of:

A 4- to 8-membered heterocyclic ring containing nitrogen and a C-alpha carbon.
Nitrile or imine-type functionality.
C-terminally linked amino acids, amino-acid analogs, peptides or peptide analogs.
Aryl, aralkyl, cycloalkyl, cycloalkenyl or heterocyclic substituents.
Boron-containing groups capable of hydrolysis to hydroxyl groups.
Phosphorus-containing substituents.
Halogenated, including fluorinated, groups.
Optional amino-protecting groups and ring substitutions.

The formula claims are not simply claims to every DPP-4 inhibitor. They require a compound to fit the stated structural variables and then to be used with metformin for Type II diabetes under claim 1.

Dependent-claim hierarchy

Claims 10 through 16 narrow the genus of claim 9 by specifying ring size, substituent identity and halogenation. Claim 17 adds a Formula II class with boron-containing functionality. Claim 18 adds Formula III. Claim 19 depends directly from claim 1 and defines a separate Formula IV class. Claim 20 adds Formula Xa or Xb classes.

This structure gives the patent several potential claim-scope positions:

A broad functional combination claim.
A potency-limited combination claim.
A peptidomimetic combination claim.
A structurally defined chemical genus used with metformin.
Narrow subgenera based on ring structure and substituents.

The structure also creates invalidity exposure. The breadth of the Markush variables, especially in claim 9 and claim 20, may invite written-description, enablement, indefiniteness and obviousness challenges. Those risks depend on the specification, prosecution history and cited prior art, which are not reproduced in the claim text.

Does US 7,459,428 cover sitagliptin, vildagliptin, saxagliptin or linagliptin?

The patent number alone does not establish that a marketed DPP-4 inhibitor falls within claims 9 through 20. Chemical coverage requires an element-by-element comparison against the complete formulae, including the structures shown in the original drawings and any incorporated definitions.

Claim 1 is different. It does not require a listed chemical structure. A marketed DPP-4 inhibitor could potentially fall within claim 1 based on its use with metformin, even if it does not fall within claims 9 through 20, subject to the non-immunosuppression limitation and other claim elements.

DPP-4 inhibitor	Potential relevance to claim 1	Formula-claim conclusion
Sitagliptin	Combination with metformin is commercially established	Requires structure-specific analysis
Vildagliptin	Combination with metformin is commercially established	Requires structure-specific analysis
Saxagliptin	Combination with metformin is commercially established	Requires structure-specific analysis
Linagliptin	Combination with metformin is commercially established	Requires structure-specific analysis
Alogliptin	Combination with metformin is commercially established	Requires structure-specific analysis
Other DPP-4 inhibitors	Potentially relevant if used with metformin	Requires claim charting

No reliable conclusion that any listed molecule is covered by the formula claims should be drawn from the abbreviated text supplied here. The missing chemical drawings are material to that determination.

What patents protect DPP-4 inhibitor and metformin combinations?

The relevant landscape has several distinct patent layers.

Combination-use patents

These claim the clinical use of metformin with a DPP-4 inhibitor. US 7,459,428 is in this category. Such patents can read on a treatment regimen even when the two active ingredients are sold separately.

Fixed-dose formulation patents

These cover tablets or other dosage forms containing metformin and a named DPP-4 inhibitor. They usually address:

Immediate-release or extended-release metformin.
Specific DPP-4 inhibitor strength.
Bilayer or multilayer tablets.
Granulation and compression parameters.
Release profiles.
Stability and impurity control.

A fixed-dose product can face both formulation-patent risk and method-of-use risk. Avoiding a fixed-dose formulation patent does not necessarily avoid a broad combination-treatment claim.

DPP-4 compound patents

These claim the active ingredient itself, its salts, polymorphs, solvates, intermediates and manufacturing processes. For products such as Januvia, Galvus, Onglyza, Tradjenta and Nesina, these patents generally present the core composition-of-matter barrier.

Method-of-use patents

Separate patents may cover:

Type II diabetes.
Combination treatment with metformin.
Initial therapy.
Add-on therapy.
Renal impairment dosing.
Cardiovascular-risk populations.
Particular dosing schedules.
Reduction of postprandial glucose or HbA1c.

Manufacturing and process patents

Process claims may protect:

Preparation of the active ingredient.
Resolution of stereoisomers.
Salt formation.
Crystallization.
Control of particle size.
Removal of genotoxic or mutagenic impurities.
Manufacture of combination tablets.

These patents can delay generic entry even after a composition-of-matter patent expires, although process patents usually create a narrower infringement theory than a product claim.

When does US 7,459,428 lose exclusivity?

The patent’s issue date is December 9, 2008. US patent term generally runs 20 years from the earliest effective nonprovisional US filing date, subject to patent-term adjustment, patent-term extension, terminal disclaimers and other statutory modifications under 35 U.S.C. §§ 154 and 156.

The expiration date cannot be calculated accurately from the issue date or claim text. A proper term calculation must identify:

The earliest effective US nonprovisional filing.
Any PCT filing and national-stage relationship.
Continuation, divisional or continuation-in-part status.
Patent-term adjustment.
Patent-term extension.
Terminal disclaimer.
Maintenance-fee payment status.

The patent is therefore not safely treated as enforceable merely because it appears in a patent database. Conversely, it should not be treated as expired without a verified term calculation.

Exclusivity distinction

Patent exclusivity and FDA regulatory exclusivity are separate.

Protection	Relevance to this patent
Patent term	Determines enforceable patent rights
FDA New Chemical Entity exclusivity	Applies to an active ingredient, not this combination-use claim as such
FDA three-year exclusivity	May cover certain approved changes supported by clinical investigations
Orphan-drug exclusivity	Applies only to qualifying orphan indications
Pediatric exclusivity	Adds six months to certain FDA exclusivity and patent periods
Orange Book listing	Depends on FDA listing eligibility and the approved drug product

US 7,459,428 is not, based on the supplied claims, a composition-of-matter patent for metformin or a named DPP-4 inhibitor. Its Orange Book significance would depend on whether an approved product sponsor listed it for an approved method of use and whether FDA accepted the listing.

What is the Orange Book status of US 7,459,428?

A patent number cannot be presumed to have an Orange Book listing. FDA listing is product-specific and generally applies to patents that claim the drug substance, drug product or an approved method of use.

For this patent, the relevant questions are:

Whether the patent was submitted by an NDA holder.
Whether the approved labeling contains the claimed metformin-plus-DPP-4-inhibitor use.
Whether FDA included the patent in the Orange Book.
Whether the patent was delisted, expired or removed.
Whether the listing covers the approved indication rather than an unapproved research use.

If listed against an NDA, a generic applicant could face a Paragraph IV certification. If not listed, a generic applicant would not ordinarily need to make a Paragraph IV certification for this patent, although the patent owner could still assert the patent outside the abbreviated approval process.

Which companies could face Paragraph IV risk?

Potentially affected parties would include sponsors and generic applicants for metformin/DPP-4 inhibitor products. The relevant branded and generic companies vary by molecule:

Product category	Originator or major sponsor	Typical patent issues
Sitagliptin plus metformin	Merck	Compound, salt, formulation and use patents
Vildagliptin plus metformin	Novartis	Compound, formulation and use patents
Saxagliptin plus metformin	AstraZeneca/Bristol Myers Squibb	Compound, formulation and use patents
Linagliptin plus metformin	Boehringer Ingelheim/Eli Lilly	Compound, formulation and use patents
Alogliptin plus metformin	Takeda	Compound, formulation and use patents

A Paragraph IV challenge to US 7,459,428 would require an ANDA applicant to assert that the patent is invalid, unenforceable or not infringed, unless the patent is omitted from the relevant Orange Book listing or otherwise outside the certification requirement.

The strongest generic positions would likely involve:

Failure to meet the “not sufficient to suppress the immune system” limitation.
Lack of proof that the accused inhibitor satisfies the claimed functional definition.
Noninfringement of the formula claims.
Indefiniteness of the immunosuppression limitation.
Lack of written description or enablement for the broad DPP-4 inhibitor genus.
Obviousness based on earlier metformin and DPP-4 inhibitor combination disclosures.
Expiration or terminal disclaimer.

How strong is the patent estate?

The estate is mixed.

Strengths

Claim 1 has broad therapeutic language and does not identify a particular DPP-4 inhibitor. Claims 21 through 24 reduce the ability to avoid the claim solely by changing dosing logistics. The patent also contains multiple fallback claim classes covering potency, oral administration, peptidomimetics and chemical formulae.

Weaknesses

The non-immunosuppression requirement is unusual and may be difficult to prove consistently in commercial infringement litigation. It also creates an indefiniteness and enablement question because the claim does not specify the assay, biological model or threshold for immune suppression.

The formula claims contain extensive variable definitions. Broad Markush claims can be valuable if adequately supported, but they are exposed where the specification does not demonstrate possession and enablement across the full claimed genus.

The patent’s commercial blocking value is lower if:

Its term has expired.
It was never listed in the Orange Book.
The relevant marketed DPP-4 inhibitor does not fit the formula claims.
The approved label does not expressly identify the claimed combination use.
The patent has been disclaimed, cancelled or rendered unenforceable.

What generic launch scenarios exist?

Scenario 1: Patent expired or unenforceable

A generic sponsor may launch after satisfying applicable FDA requirements, subject to separate active-ingredient, formulation and manufacturing patents.

Scenario 2: Patent listed but not blocking approval

An ANDA applicant may submit a Paragraph IV certification. The NDA holder may sue within the statutory period, potentially triggering a 30-month stay under the Hatch-Waxman framework.

Scenario 3: Patent listed and asserted

Launch timing would depend on litigation, settlement terms, preliminary-injunction proceedings and the strength of the noninfringement or invalidity defenses.

Scenario 4: Separate components

A company selling metformin and a DPP-4 inhibitor separately may still face method-of-use allegations if its labeling, promotional conduct or induced-use evidence supports infringement. Product separation does not automatically avoid a method claim.

Scenario 5: Label carve-out

A generic applicant may seek to omit a patented indication from labeling where FDA permits a section viii statement. That approach is less effective if the patented use is inseparable from the approved labeling or if the patent owner asserts induced infringement based on the remaining label.

What litigation and settlement issues matter?

A complete litigation assessment requires the federal court docket, Patent Trial and Appeal Board records, FDA Orange Book history and current patent-register information. The claim text alone does not establish whether US 7,459,428 has been litigated, challenged, settled or cancelled.

For business analysis, the key diligence points are:

Whether any district-court case asserted the patent.
Whether a Paragraph IV notice letter identified it.
Whether the patent was included in a generic settlement.
Whether the settlement contains a licensed-entry date.
Whether any inter partes review or post-grant proceeding challenged the claims.
Whether a terminal disclaimer links the patent to an earlier patent.
Whether maintenance fees were paid.
Whether FDA lists the patent for an approved product.

How does this patent compare with compound and formulation patents?

US 7,459,428 is generally weaker than a valid composition-of-matter patent against a specific DPP-4 inhibitor because it depends on use, combination and functional limitations.

Patent type	Typical enforceability against a DPP-4 product
Composition-of-matter patent	High if the active ingredient is covered and patent remains in force
Salt or polymorph patent	Medium to high, depending on product form
Fixed-dose formulation patent	Medium; depends on product architecture
Manufacturing patent	Narrower; depends on process evidence
Combination-use patent	Variable; depends on label, use and claim construction
US 7,459,428	Potentially broad, but materially exposed to proof and validity challenges

The patent’s value is highest where a product’s approved label expressly recommends metformin coadministration and the patent remains enforceable. Its value is lower where the product is used outside the claimed indication, where the label does not encourage the combination, or where the DPP-4 inhibitor does not satisfy the structural or functional limitations.

Key Takeaways

US 7,459,428 is principally a combination-treatment patent for metformin plus a DPP-4 inhibitor in Type II diabetes.
Claim 1 is broader than the formula claims because it does not identify a specific inhibitor.
The “not sufficient to suppress the immune system” limitation is central to both infringement and validity analysis.
Claims 21 through 24 cover simultaneous, sequential, separate and same-composition administration.
Claims 9 through 20 require detailed chemical mapping; the abbreviated claim text omits drawings material to that analysis.
The patent does not establish composition-of-matter protection for sitagliptin, vildagliptin, saxagliptin, linagliptin or alogliptin.
Patent expiration cannot be calculated from the issue date alone.
Orange Book and Paragraph IV relevance is product-specific and cannot be inferred solely from the patent number.
Separate compound, formulation, method-of-use and process patents may present greater launch barriers than this combination patent.
Generic risk depends on patent term, Orange Book listing, approved labeling, claim construction, litigation history and settlement terms.

FAQs About US Patent 7,459,428

Does US 7,459,428 cover metformin by itself?

No. The claims require conjoint administration of metformin with a DPP-4 inhibitor. Metformin monotherapy does not satisfy claim 1.

Does the patent require a fixed-dose combination tablet?

No. Claims 21 through 24 expressly encompass separate, sequential, simultaneous and same-composition dosing.

Can a DPP-4 inhibitor be outside the formula claims but still implicate claim 1?

Yes. Claim 1 is functionally drafted and does not require the inhibitor to satisfy Formula I, II, III, IV, Xa or Xb.

Is the patent a patent on DPP-4 inhibitor chemistry?

No. It is a method patent. The chemical formula claims are dependent or combination-use claims, not standalone composition claims.

What is the main invalidity risk?

The principal risks are indefiniteness and enablement relating to the immunosuppression limitation, together with written-description and obviousness challenges to the broad functional and Markush claim scope.

References

U.S. Patent No. 7,459,428, “Methods of treating diabetes using dipeptidyl peptidase IV inhibitors,” issued December 9, 2008.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.
U.S. Food and Drug Administration. (2024). Guidance for industry: 180-day exclusivity under the Hatch-Waxman amendments. FDA.
U.S. Patent and Trademark Office. (2024). Manual of patent examining procedure, Chapter 2700: Patent term. USPTO.
35 U.S.C. §§ 154, 156, 271, 282 and 355.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2003264609	⤷ Start Trial
Australia	2493599	⤷ Start Trial
Australia	766219	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Summary for Patent: 7,459,428